Nkarta (NKTX) Total Non-Current Liabilities (2019 - 2026)
Nkarta's (NKTX) quarterly Total Non-Current Liabilities came in at $86.1 million in Q1 2026, down 6.1% year-on-year from $91.7 million in Q1 2025, and down 6.18% quarter-over-quarter from $91.8 million in Q4 2025.
Nkarta (NKTX) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Nkarta's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $86.1 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 6.1% year-over-year to $86.1 million in Q1 2026; TTM through Mar 2026 was $86.1 million, a 6.1% decrease from a year earlier, with the FY2025 full-year figure at $91.8 million, down 1.44% from the prior year.
- Total Non-Current Liabilities slipped to $86.1 million in Q1 2026 per NKTX's latest filing, from $91.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $104.5 million in Q3 2022 and bottomed at $77.6 million in Q1 2022.
- The 4-year median for Total Non-Current Liabilities is $90.6 million (2025), against an average of $89.7 million.
- Across the five-year window, Total Non-Current Liabilities surged 366.69% in 2022 and retreated 6.1% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $104.5 million in 2022, then dropped by 10.9% to $93.1 million in 2024, then retreated by 1.44% to $91.8 million in 2025, then declined by 6.18% to $86.1 million in 2026.
- Per Business Quant, the three latest NKTX Total Non-Current Liabilities figures stand at $86.1 million (Q1 2026), $91.8 million (Q4 2025), and $89.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | 86.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.13 Mn |
| Dec 31, 2025 | 91.80 Mn |
| Sep 30, 2025 | 89.25 Mn |
| Jun 30, 2025 | 90.56 Mn |
| Mar 31, 2025 | 91.72 Mn |
| Dec 31, 2024 | 93.14 Mn |
| Sep 30, 2022 | 104.53 Mn |
| Jun 30, 2022 | 82.59 Mn |
| Mar 31, 2022 | 77.58 Mn |
| Dec 31, 2021 | 22.92 Mn |
| Sep 30, 2021 | 22.40 Mn |
| Jun 30, 2021 | 20.66 Mn |
| Mar 31, 2021 | 19.63 Mn |
| Dec 31, 2020 | 16.35 Mn |
| Sep 30, 2020 | 17.22 Mn |
| Jun 30, 2020 | 67.57 Mn |
| Dec 31, 2019 | 13.95 Mn |